Myriad Prepared to Make Small IP Sacrifice to Aussies in Light of Landmark US Patent Case

In deciding to surrender a key patent to the Australian government, it seems Myriad may be preparing to sacrifice a small slice of its IP holdings in a secondary market in an effort to avoid any erosion of its position in the landmark US case challenging seven of its BRCA gene patents.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.